-
81.发明授权Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals 失效用于鉴定患有细胞异常的个体的方法，其一些异常细胞呈现HLA-A2 /酪氨酸酶衍生肽的复合物，以及用于治疗所述个体的方法
公开(公告)号：US5747271A
公开(公告)日：1998-05-05
申请号：US636676
申请日：1996-04-23
申请人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wolfel
发明人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wolfel
IPC分类号： A61K39/00 , C07K14/47 , G01N33/569 , G01N33/53 , C12N5/08 , G01N33/566 , G01N33/567
CPC分类号： G01N33/56972 , C07K14/4748 , A61K39/00 , Y10S436/813
摘要： The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
摘要翻译： 本发明涉及在异常细胞表面鉴定HLA-A2和酪氨酸酶衍生肽的复合物。 该观察的治疗和诊断结果是本发明的主题。
-
82.发明授权Cytolytic T cell lines which bind to complexes of tumor rejection antigens and HLA-B44 molecules 失效结合肿瘤排斥抗原和HLA-B44分子的复合物的细胞溶解T细胞系
公开(公告)号：US5744353A
公开(公告)日：1998-04-28
申请号：US796883
申请日：1997-02-06
申请人： Jean Herman , Pierre Coulie , Thierry Boon-Falleur , Pierre van der Bruggen , Immanuel Luescher
发明人： Jean Herman , Pierre Coulie , Thierry Boon-Falleur , Pierre van der Bruggen , Immanuel Luescher
IPC分类号： C12N15/09 , A61K35/14 , A61K39/00 , C07K7/06 , C07K14/47 , C07K14/74 , C12N1/02 , C12N5/08 , C12N5/10 , C12Q1/68 , G01N33/569 , G01N33/574 , G01N33/68 , C12N5/06
CPC分类号： C12Q1/6881 , C07K14/4748 , C07K14/70539 , C12Q1/6886 , G01N33/56977 , G01N33/57492 , A61K39/00 , C12Q2600/136
摘要： Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.
摘要翻译： 描述了由HLA-B44分子呈递的肿瘤排斥抗原。 这些肽可用于诊断和治疗方法。 肿瘤排斥抗原来自MAGE肿瘤排斥抗原前体。
-
公开(公告)号：US5744316A
公开(公告)日：1998-04-28
申请号：US587391
申请日：1996-01-17
IPC分类号： C12N15/09 , A61K31/00 , A61K35/14 , A61K35/76 , A61K38/00 , A61K38/46 , A61K39/00 , A61K45/00 , A61K48/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P43/00 , C07K7/06 , C07K14/47 , C07K14/74 , C12N9/02 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/566 , G01N33/569 , A61K38/04 , A61K39/385
CPC分类号： C12Y114/18001 , C07K14/4748 , C07K14/70539 , C12N9/0071 , G01N33/505 , G01N33/5091 , G01N33/56972 , A61K38/00 , A61K39/00 , A61K48/00
摘要： The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
-
84.发明授权Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules 失效对MAGE相关肽和HLA分子的复合物分离的分离的溶细胞T细胞
公开(公告)号：US5695994A
公开(公告)日：1997-12-09
申请号：US443341
申请日：1995-05-17
申请人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
发明人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
IPC分类号： G01N33/53 , A61K35/16 , A61K38/00 , A61K39/00 , A61K39/395 , A61P37/00 , C07K1/00 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C07K17/00 , C12N5/10 , C12N15/09 , C12N15/11 , C12P21/02 , C12P21/08 , G01N33/574 , G01N33/577 , C12N5/06 , C12N5/08
CPC分类号： C07K14/4748 , C07K16/30 , A61K38/00 , A61K39/00
摘要： The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及衍生自由MAGE-3基因编码的肿瘤排斥抗原前体的非肽。 这种非肽由HLA分子HLA-A1呈递。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
85.发明授权Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof 失效衍生自MAGE-2的分离的肽，对肽和HLA-A2分子的复合物特异的细胞溶解性T细胞及其用途
公开(公告)号：US5686068A
公开(公告)日：1997-11-11
申请号：US687226
申请日：1996-07-25
申请人： Cornelius J. M. Melief , M. W. Visseren , Sjoerd van der Burg , Pierre van der Bruggen , Thierry Boon-Falleur
发明人： Cornelius J. M. Melief , M. W. Visseren , Sjoerd van der Burg , Pierre van der Bruggen , Thierry Boon-Falleur
IPC分类号： A61K39/00 , A61K35/26 , A61K38/00 , A61K38/04 , A61K39/395 , A61P35/00 , A61P37/00 , C07K5/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/74 , C07K16/28 , C12N5/00 , C12P21/08 , A61K38/08 , C07K14/82 , C12N5/06
CPC分类号： C07K14/705 , C07K14/4748 , A61K2039/5158 , A61K38/00 , A61K39/00 , Y10S530/828
摘要： New peptides derived from the MAGE-2 molecule and which bind to HLA-A*0201 molecules are disclosed. Some of these are especially useful because, when complexed to their HLA-A*0201 partner molecules, they induce CTL proliferation.
摘要翻译： 公开了衍生自MAGE-2分子并且结合HLA-A * 0201分子的新肽。 其中一些是特别有用的，因为当与HLA-A * 0201配偶体分子复合时，它们诱导CTL增殖。
-
86.发明授权Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof 失效对应于肿瘤排斥抗原前体细胞中的氨基酸序列的肿瘤排斥抗原及其用途
公开(公告)号：US5683886A
公开(公告)日：1997-11-04
申请号：US196630
申请日：1994-02-15
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07H21/02 , C07H21/04 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/74 , C12N1/21 , C12N5/10 , C12N15/12 , C12P21/02 , C12R1/91 , C01N33/53 , C07K14/82 , C01N33/574
CPC分类号： C07K14/4748 , C07K14/70539 , A61K38/00
摘要： A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一种新的肿瘤排斥抗原前体家族及其编码的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
公开(公告)号：US5519117A
公开(公告)日：1996-05-21
申请号：US233305
申请日：1994-04-26
IPC分类号： C12N15/09 , A61K35/14 , A61K35/17 , A61K38/00 , A61K38/46 , A61K39/00 , A61K48/00 , A61P35/00 , A61P37/00 , A61P37/02 , C07K7/06 , C07K14/47 , C07K14/74 , C12N5/08 , C12N9/02 , C12P21/02 , C12Q1/04 , C12R1/91 , G01N33/50 , G01N33/569 , C07K7/00
CPC分类号： G01N33/56972 , A61K35/17 , C07K14/4748 , C07K14/70539 , C12N9/0071 , C12Y114/18001 , G01N33/505 , G01N33/5091 , A61K38/00 , A61K39/00 , A61K48/00
摘要： The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
-
88.发明授权Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3 失效通过测定法师-3确定头颈鳞状细胞癌，前列腺癌和膀胱肿瘤的方法
公开(公告)号：US5512437A
公开(公告)日：1996-04-30
申请号：US204727
申请日：1994-03-01
申请人： Beatrice Gaugler , Thierry Boon-Falleur , Benoit van den Eynde , Etienne DePlaen , Francis Basseur , Bernard Lethe , Pierre van der Bruggen
发明人： Beatrice Gaugler , Thierry Boon-Falleur , Benoit van den Eynde , Etienne DePlaen , Francis Basseur , Bernard Lethe , Pierre van der Bruggen
CPC分类号： C07K14/4748 , C12Q1/6886 , C12Q2600/158
摘要： A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.
摘要翻译： 描述了确定头颈鳞状细胞癌，膀胱肿瘤和前列腺癌的方法。 该方法包括测定编码肿瘤排斥抗原前体MAGE-3或其表达产物的基因的表达。 描述了可用于这些测定的各种测定和试剂盒。
-
89.发明授权
公开(公告)号：US5462871A
公开(公告)日：1995-10-31
申请号：US073103
申请日：1993-06-07
申请人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
发明人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
IPC分类号： G01N33/53 , A61K38/00 , A61K39/00 , A61K39/395 , A61P37/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/10 , C12N5/12 , C12N5/18 , C12N15/09 , C12P21/02 , C12P21/08 , G01N33/574 , G01N33/577 , C12N15/12 , C12N1/21
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , A61K39/00
摘要： The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
摘要翻译： 本发明涉及编码衍生自MAGE肿瘤排斥抗原前体的非肽的分离的核酸分子。 非肽与细胞表面呈现的人白细胞抗原形成复合物，并导致细胞溶解性T淋巴细胞裂解这些细胞。 因此，它们在诊断方法中是有用的。 本发明的一部分也是设计用于编码已经用本发明的分离的核酸分子转化或转染的非肽以及包含这些分子的载体的细胞系的载体。
-
公开(公告)号：US20120196363A1
公开(公告)日：2012-08-02
申请号：US13429873
申请日：2012-03-26
IPC分类号： C12N5/02
CPC分类号： A61K31/7016 , A61K31/4745 , A61K45/06 , A61K2039/5158 , C07K14/7051 , C07K14/70517 , C12N5/0636 , C12N2500/22 , C12N2500/34 , C12N2501/59 , C12N2501/73 , G01N33/505 , A61K2300/00
摘要： The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.
摘要翻译： 本发明涉及调节T淋巴细胞活性的方法和组合物。 已经发现，两种T淋巴细胞受体，特别是TCR和CD8在T淋巴细胞表面上彼此间隔一定距离。 通过使用改变这些受体之间距离的调节剂，调节T淋巴细胞的活性。
-
-
-
-
-
-
-
-
-
搜索结果
161 条记录 (耗时 0.041 秒)
